Login to Your Account



EMA Issues Negative Opinion for AMT's Gene Therapy

By Nuala Moran


Monday, June 27, 2011
LONDON – The European Medicines Agency (EMA) has knocked back Amsterdam Molecular Therapeutics NV's (AMT) Glybera, leaving the winning post in the race to be the first approved gene therapy in a registered market still some distance away.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription